2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2628

Hydroxychloroquine and Prednisone Have Different Effects on Antiphospholipid Antibodies in SLE, with Hydroxychloroquine Not Reducing IgA Anticardiolipin
Abstract Number: 2668

Hydroxychloroquine and the Risk of Thrombotic Events in Systemic Lupus Erythematosus Patients : A Systematic Review and Meta-Analysis
Abstract Number: 2631

Hydroxychloroquine Blood Levels Are Significantly Associated with Cardiovascular Risk Factors
Abstract Number: 2897

Hydroxychloroquine Blood Levels Show Significant Trend Test for Risk of Retinopathy
Abstract Number: 2641

Hydroxychloroquine Could Modulate S100 Proteins Expression, Which Reflect the Activity of Lupus Nephritis or Skin Lesion, in Systemic Lupus Erythematosus Patients with Low Disease Activity
Abstract Number: 2637

Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus
Abstract Number: 1244

Hydroxychloroquine Quality Improvement Project at UF Health Jacksonville Rheumatology Clinics
Abstract Number: 1181

Hydroxychloroquine: Do We All See Eye to Eye? a Single-Site Analysis of Hydroxychloroquine Dosing Compared to 2016 American Academy of Ophthalmology Guidelines
Abstract Number: 1629

Hyperlipoproteinemia (a) in Patients with Spondyloarthritis. Results of the CARMA Study
Abstract Number: 236

Hypogammaglobulinemia and Infection Risk in Patients Treated with Rituximab
Abstract Number: 1080

Hypomethylation of STAT1 and HLA-DRB1 in CD8+ T Cells Is Associated with Type-I Interferon-Dependent HLA-DRB1 Overexpression and Activation of Autologous CD4+ T Cells in Systemic Lupus Erythematosus
Abstract Number: 117

Hypomorphic A20 Expression Modulates Fibrosis Susceptibility: Implications for Systemic Sclerosis?
Abstract Number: 1669

iC3b/C3 Ratios More Strongly Correlate with SLE Disease Activity in African-Americans Compared to Whites
Abstract Number: 104

Identification of a Gut Pathobiont Immunostimulatory Lipoglycan Antigen Linked to Lupus Nephritis
Abstract Number: 2005

Identification of a Human Cartilage Microbial DNA Signature and Characterization of Distinct Microbiome Profiles Associated with Osteoarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].